Open main menu

Psychiatrienet β

Moclobemide-trazodone

Revision as of 08:26, 21 July 2009 by Walter (talk | contribs)
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide
Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone

Switch medication from moclobemide to trazodone.[1] [2]

Nietinrijdenbord.png Stop moclobemide
  • Before day 0: gradually reduce dosage of moclobemide to a maximum of 300 mg/day, when this dosage is > 300 mg/day.
  • Day 1: reduce dosage of moclobemide to 150 mg/day.
  • Day 8: stop administration of moclobemide.
Eenrichtingbord.png Start trazodone
  • Day 8-9: a wash-out period of two days is necessary.
  • Day 10: start administration of trazodone in a dosage of 100 mg/day.
  • Day 17: if necessary, increase the dosage of trazodone to a maximum of 400 mg/day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possilble, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.